Cardiac Mapping Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Contact Cardiac Mapping Systems, Non-Contact Cardiac Mapping Systems), By Indication (Atrial Fibrillation, Atrial Flutter, Others), By End-use (Hospitals, Diagnostic Centers, Others), By Region & Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 2.99 Billion
CAGR (2026-2031)	11.32%
Fastest Growing Segment	Contact Cardiac Mapping Systems
Largest Market	North America
Market Size (2031)	USD 5.69 Billion

Market Overview

The Global Cardiac Mapping Devices Market will grow from USD 2.99 Billion in 2025 to USD 5.69 Billion by 2031 at a 11.32% CAGR. Cardiac mapping devices are diagnostic technologies utilized during electrophysiology procedures to visualize and analyze the electrical activity of the heart. These systems employ catheter-based sensors to construct detailed three-dimensional models of cardiac chambers, enabling physicians to precisely locate the anatomical origins of complex arrhythmias such as atrial fibrillation. By providing real-time electrical information, these tools guide ablation catheters to the specific tissue causing irregular heartbeats, thereby facilitating effective treatment and improving patient outcomes in the field of electrophysiology.

The market is primarily driven by the escalating global prevalence of cardiovascular diseases and an aging population increasingly susceptible to rhythm disorders. This fundamental demand is further supported by the clinical shift toward minimally invasive ablation procedures which require precise navigational capabilities. According to the European Society of Cardiology, in 2025, one in three people worldwide will develop a potentially life-threatening heart rhythm disorder in their lifetime. Despite this strong clinical need, market expansion faces a significant challenge due to the high acquisition and maintenance costs of these systems which can limit accessibility in price-sensitive developing healthcare infrastructures.

Key Market Drivers

The escalating global prevalence of cardiovascular diseases and arrhythmias drives significant market momentum. The rising incidence of complex rhythm disorders like atrial fibrillation creates a critical need for advanced mapping systems to guide curative ablation procedures. This epidemiological burden directly translates into higher procedural volumes and demand for precise diagnostic tools. According to the American Heart Association, January 2024, in the '2024 Heart Disease and Stroke Statistics: A Report of US and Global Data', cardiovascular disease remains the leading cause of death globally, claiming approximately 19.91 million lives annually. Further emphasizing the scale of the addressable market, according to the National Heart, Lung, and Blood Institute, in 2024, new estimates indicate that at least 10.55 million American adults are predicted to have atrial fibrillation, a prevalence three times higher than previous projections.

Technological advancements in 3D electro-anatomical mapping and the integration of artificial intelligence further propel the market. Market leaders are rapidly deploying high-density multi-electrode catheters and AI-driven software that automate the identification of arrhythmogenic substrates, enhancing procedural efficiency. These innovations address the clinical demand for precision in complex electrophysiology cases. The commercial traction of these next-generation technologies is robust. According to Abbott, October 2024, in the 'Third-Quarter 2024 Results', the company's Electrophysiology sales grew 14.3 percent on an organic basis, driven specifically by double-digit growth in cardiac mapping-related products. This performance validates the industry-wide shift toward sophisticated, tech-enabled diagnostic solutions.

Download Free Sample Report

Key Market Challenges

The substantial financial investment required for acquiring and maintaining cardiac mapping systems constitutes a primary restraint on market progression. Healthcare facilities, particularly in developing regions, often find the initial capital expenditure prohibitive. This barrier extends to ongoing expenses for specialized catheters and technical maintenance, which increases the total cost of ownership significantly. Consequently, hospitals with limited funding often delay technology upgrades or rely on conventional methods, directly restricting the installed base of mapping units and reducing the potential revenue stream for manufacturers in these territories.

This economic hurdle creates a distinct gap between clinical necessity and actual technology adoption. While the patient population requiring arrhythmia management expands, the financial rigidity of healthcare budgets limits the penetration of these devices. According to the World Heart Federation, in 2024, cardiovascular diseases were responsible for approximately 20.5 million deaths globally, highlighting an urgent volume of patients requiring effective intervention tools. However, because budget allocations often cannot accommodate the premium pricing of advanced mapping technologies, manufacturers face difficulties expanding into price-sensitive markets, thereby slowing the overall growth trajectory of the industry.

Key Market Trends

The convergence of cardiac mapping with Pulsed Field Ablation (PFA) technologies is rapidly reshaping the competitive landscape. As PFA systems gain clinical preference for their ability to deliver rapid, non-thermal isolation of pulmonary veins, mapping platforms are evolving to provide seamless integration with these novel catheters. This technological synergy ensures precise visualization of catheter placement and lesion durability without the extensive point-by-point mapping required by traditional radiofrequency methods. The impact of this integration is profound, as evidenced by the immediate commercial success of early entrants. According to MedTech Dive, October 2024, in the article 'Boston Scientific boosts PFA expectations, citing rapid Farapulse adoption', the company's electrophysiology sales climbed 177% in the third quarter compared to the prior year, a surge driven primarily by the high demand for its PFA system and compatible mapping tools.

Simultaneously, the industry is witnessing a shift to non-contact and non-invasive mapping solutions designed to streamline procedural workflows and enhance safety. These advanced systems utilize body-surface electrodes and sophisticated computational modeling to reconstruct 3D electrical maps of the heart before invasive catheters are introduced. This approach significantly reduces the time required for intra-procedural mapping and minimizes patient exposure to ionizing radiation. Validating the operational benefits of this methodology, according to Vektor Medical, April 2024, in the 'Vektor Medical Announces Publication of vMap Study Results', clinical data demonstrated that the use of their non-invasive AI-based mapping technology resulted in a 43.7% reduction in fluoroscopy duration during arrhythmia ablation procedures compared to the standard of care.

Segmental Insights

The Contact Cardiac Mapping Systems segment represents the fastest-growing category within the Global Cardiac Mapping Devices Market. This growth is primarily driven by the high utility of these systems in catheter ablation procedures, where direct tissue contact ensures accurate electrical data collection. Physicians prioritize these tools for diagnosing complex arrhythmias due to their ability to generate high-resolution anatomical models. Furthermore, ongoing authorizations by regulatory entities such as the U.S. FDA for new contact-based technologies continue to validate their safety and efficacy, thereby accelerating clinical adoption across major healthcare facilities globally.

Regional Insights

North America maintains the leading position in the Global Cardiac Mapping Devices Market due to the rising prevalence of arrhythmias and a robust healthcare infrastructure. The region benefits from the widespread adoption of mapping technologies and favorable reimbursement structures that enable broader patient access. Market growth is further sustained by the concentration of key industry players and frequent regulatory clearances from the U.S. Food and Drug Administration (FDA). These factors, combined with significant research initiatives in the United States, ensure the continued prominence of North America in the global landscape.

Recent Developments

• In September 2025, Kardium secured premarket approval from the U.S. FDA for its Globe Pulsed Field System, along with clearances for its specialized mapping software and introducer sheath. The Globe System features a catheter with a spherical array of 122 electrodes, capable of performing high-density mapping and targeted ablation in a single device. The Chief Executive Officer of Kardium described the approval as a significant milestone, enabling the commercial launch of a comprehensive solution for atrial fibrillation. The system offers real-time thermal contact sensing and allows for the isolation of pulmonary veins with a single application, streamlining the treatment process.
• In October 2024, Medtronic received approval from the U.S. Food and Drug Administration for the Affera Mapping and Ablation System used in conjunction with the Sphere-9 Catheter. This all-in-one technology integrates high-density mapping with both pulsed field and radiofrequency ablation capabilities, allowing physicians to treat persistent atrial fibrillation without switching catheters. The President of the Cardiac Ablation Solutions business at Medtronic highlighted that the system addresses unmet patient needs by providing a safe and effective solution for complex heart conditions. The approval positioned the company as a leader in offering dual-energy ablation therapies integrated with advanced mapping visualization.
• In October 2024, Boston Scientific obtained U.S. FDA approval for the FARAWAVE NAV Ablation Catheter and clearance for the FARAVIEW Software, designed to enhance the capabilities of its pulsed field ablation system. These new technologies enable magnetic navigation and provide dynamic visualization of the catheter's placement and shape during cardiac procedures. The President of Electrophysiology at Boston Scientific noted that these tools allow for a seamless mapping experience, minimizing the need for device exchanges and reducing fluoroscopy times. The integrated solution is compatible with the company’s existing cardiac mapping technologies, aiming to improve workflow efficiency for clinicians.
• In May 2024, Biosense Webster, a subsidiary of Johnson & Johnson MedTech, announced the launch of the CARTO 3 System Version 8, the latest iteration of its three-dimensional heart mapping platform. This software update introduced advanced modules such as CARTOSOUND FAM and CARTO ELEVATE, which utilize artificial intelligence to improve the efficiency and accuracy of cardiac ablation procedures. The President of Biosense Webster stated that the new system utilizes machine learning to automatically generate anatomical maps and enhance signal analysis. This development aims to streamline workflows for electrophysiologists by reducing the need for manual contouring during the treatment of arrhythmias.

Key Market Players

• Abbott
• Biosense Webster
• Boston Scientific
• Siemens Healthineers
• Medtronic
• Acutus Medical
• Boston Scientific
• GE Healthcare
• Philips
• MicroPort

By Type	By Indication	By End-use	By Region
Contact Cardiac Mapping Systems Non-Contact Cardiac Mapping Systems	Atrial Fibrillation Atrial Flutter Others	Hospitals Diagnostic Centers Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Cardiac Mapping Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Cardiac Mapping Devices Market, By Type:

• Contact Cardiac Mapping Systems
• Non-Contact Cardiac Mapping Systems

• Cardiac Mapping Devices Market, By Indication:

• Atrial Fibrillation
• Atrial Flutter
• Others

• Cardiac Mapping Devices Market, By End-use:

• Hospitals
• Diagnostic Centers
• Others

• Cardiac Mapping Devices Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE